Highest-materiality recent filing
STAAR Surgical Q1 net sales up 119.6% to $93.5M; returns to profitability with GAAP EPS $0.10
Record Q1 net sales of $93.5M, up 119.6% YoY, driven by China recovery and U.S. growth.
STAAR Surgical prelim Q1 2026 net sales expected >$90M, up from $42.6M YoY
Net sales expected to exceed $90M in Q1 2026, more than double prior year's $42.6M.
STAAR Surgical appoints interim co-CEOs; reports China stabilization, EVO+ launch, cost cuts
Warren Foust and Deborah Andrews named Interim Co-CEOs after Alcon merger rejected by shareholders in Jan 2026.
STAAR Surgical appoints interim co-CEOs after CEO Farrell steps down; global CEO search launched
Stephen C. Farrell stepped down as CEO effective Jan 31, 2026, per prior cooperation agreement with Broadwood Partners.
STAAR Surgical elects new Board Chair; forms CEO Search Committee
Neal C. Bradsher (Broadwood Capital, largest stockholder) elected Board Chair effective Jan 15, 2026.
STAAR Surgical CEO Farrell to step down Jan 31; Broadwood appoints three new directors
CEO Stephen Farrell to step down as CEO by Jan 31, 2026; will remain as consultant for 1 year at $45k/month.
STAAR Surgical shareholders vote down Alcon merger; deal terminated
Preliminary vote tally failed to secure enough shareholder approval for the Alcon merger at special meeting on Jan 6, 2026.
STAAR Surgical's merger with Alcon terminated after shareholder vote; no fee
Merger agreement with Alcon terminated effective Jan 6, 2026; no termination fee payable.
Alcon raises STAAR Surgical acquisition price to $30.75 per share from $28.00
Merger consideration increased to $30.75/share in cash, up from $28.00/share (approx. 9.8% increase).
STAAR's go-shop period expires with no competing bids; 21 parties contacted, none submitted proposal
Go-shop period expired December 6, 2025; no competing acquisition proposals received.
30-day go-shop period through Dec 6, 2025; STAAR may actively solicit third-party proposals.
STAAR postpones special meeting on Alcon merger to Dec 3 amid ongoing discussions
Special meeting of stockholders postponed from Nov 6 to Dec 3, 2025; new record date: Oct 24, 2025.
STAAR adjourns special meeting on Alcon merger to Nov 6, 2025
Special meeting scheduled for Oct 23, 2025 adjourned to 8:30 a.m. PT on Nov 6, 2025.
STAAR Surgical announces preliminary Q3 net sales $94.7M (+6.9%); includes $25.9M China shipment
Preliminary net sales $94.7M, up 6.9% YoY from $88.6M; outside China grew 7.7%.
STAAR Surgical supplements proxy for Alcon merger; faces lawsuits, Broadwood opposition
Two shareholder lawsuits filed Oct 1 in NY state court alleging proxy misrepresentations; demand letters also received.
STAAR urges stockholders to vote FOR Alcon merger at $28/sh, citing 59% VWAP premium
Alcon merger offers $28.00 per share cash; 51% premium to Aug 4 close, 59% to 90-day VWAP.
Alcon to acquire STAAR Surgical for $28/share in cash, ~$1.5B equity value
Alcon pays $28/share cash, a ~59% premium to STAAR's 90-day VWAP and 51% premium to Aug 4 close.
Deborah Andrews appointed CFO effective June 25, 2025; she served as interim CFO since March 2025 and previously held the role from 2007-2013 and 2017-2020.
STAAR Surgical announces $30M buyback and China NMPA approval for EVO+ TICL
Authorized $30M share repurchase program, expected to run over six months from cash on hand.
On June 25, 2025, STAAR Surgical Company (the “Company”) announced that its Board of Directors (the “Board”) appointed Deborah Andrews as Chief Financial Officer of the Company, effective June 25, 2025 (the “Effective Date”).
Max materiality 0.90 · Median 0.70 · Most common event m_and_a